← Leaderboards
Isabella Hetherington
University Of South Florida
$116,842
Attributed
$116,842
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $39.8K · FY2023–25$50K$37.5K$25K$12.5K$0
'23
'24
'25
Funding mix
By agency
NIH$116,842 · 1
By mechanism
F31$116,842 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of South Florida
Same institution · by research overlap
- Hana Totary-Jain$5,502,512
- Da-Zhi Wang$21,157,099
- David W Russ$149,500
Others in their field
Other Rising Stars on “Adverse Effects”
- Cynthia M Visness · Rho Federal Systems Division, Inc.$14,006,776
- Cathie Snyder · Rho Federal Systems Division, Inc.$13,500,724
- Dawn Fallacara · Battelle Centers/Pub Hlth Res & Evaluatn$12,449,418
- Benjamin M Greenberg · Ut Southwestern Medical Center$11,474,975
- Jinsy Andrews · Columbia University Health Sciences$11,474,975
- Eric Anderson · Columbia University Health Sciences$11,474,975
Research focus
Adverse Effects5&AposApolipoprotein EArterial Fatty StreakArteriesAnti-Inflammatory AgentsAtherosclerosisBinding SitesCardiacCareerCause Of DeathCell AssemblyCell CycleCell MotilityCell PhysiologyCell ProliferationCellsCell SeparationCell TypeChronicClinically RelevantClinical TrialsColchicineCollege
Grant awards (3)
Development of a novel site-and cell-selective mRNA therapeutic to treat atherosclerosis$39,750
F31 · FY2025 · HL · contact PI
Development of a novel site-and cell-selective mRNA therapeutic to treat atherosclerosis$39,186
F31 · FY2024 · HL · contact PI
Development of a novel site-and cell-selective mRNA therapeutic to treat atherosclerosis$37,906
F31 · FY2023 · HL · contact PI